NO851535L - Nye polypeptider med blodkoaguleringshemmende virkning, fremgangsmaate til deres fremstilling resp. utvinnelse, deres anvendelse og midler inneholdende disse - Google Patents
Nye polypeptider med blodkoaguleringshemmende virkning, fremgangsmaate til deres fremstilling resp. utvinnelse, deres anvendelse og midler inneholdende disseInfo
- Publication number
- NO851535L NO851535L NO851535A NO851535A NO851535L NO 851535 L NO851535 L NO 851535L NO 851535 A NO851535 A NO 851535A NO 851535 A NO851535 A NO 851535A NO 851535 L NO851535 L NO 851535L
- Authority
- NO
- Norway
- Prior art keywords
- polypeptide
- val
- formula
- peptide
- acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 45
- 229920001184 polypeptide Polymers 0.000 title claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title description 3
- 239000008280 blood Substances 0.000 title description 2
- 230000001112 coagulating effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 241000545744 Hirudinea Species 0.000 claims description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 102000007625 Hirudins Human genes 0.000 claims description 6
- 108010007267 Hirudins Proteins 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 6
- 229940006607 hirudin Drugs 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 241000237903 Hirudo Species 0.000 claims description 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 150000001371 alpha-amino acids Chemical class 0.000 claims description 4
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 3
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000004459 forage Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- -1 Cit Chemical compound 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000237902 Hirudo medicinalis Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001601 blood-air barrier Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009424 thromboembolic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- AHEZEFWRBPPAGP-UHFFFAOYSA-N 3,3a-dihydro-2h-indene-1,4-dione Chemical compound O=C1CCC2C1=CC=CC2=O AHEZEFWRBPPAGP-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical class C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 1
- NDZFORWVONADMI-UHFFFAOYSA-N 4-phenyl-5h-1,3-thiazol-2-one Chemical compound O=C1SCC(C=2C=CC=CC=2)=N1 NDZFORWVONADMI-UHFFFAOYSA-N 0.000 description 1
- SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 1
- 241000243818 Annelida Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003827 Plasma Kallikrein Human genes 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 150000002976 peresters Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3414593 | 1984-04-18 | ||
| DE19843438296 DE3438296A1 (de) | 1984-04-18 | 1984-10-19 | Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO851535L true NO851535L (no) | 1985-10-21 |
Family
ID=25820510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO851535A NO851535L (no) | 1984-04-18 | 1985-04-17 | Nye polypeptider med blodkoaguleringshemmende virkning, fremgangsmaate til deres fremstilling resp. utvinnelse, deres anvendelse og midler inneholdende disse |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US4668662A (da) |
| EP (1) | EP0158986B1 (da) |
| JP (1) | JP2552263B2 (da) |
| KR (1) | KR930000054B1 (da) |
| AR (1) | AR242800A1 (da) |
| AU (1) | AU580295B2 (da) |
| CA (1) | CA1271298A (da) |
| DE (2) | DE3438296A1 (da) |
| DK (1) | DK171824B1 (da) |
| ES (3) | ES8605772A1 (da) |
| FI (1) | FI851521L (da) |
| GR (1) | GR850942B (da) |
| HU (1) | HU198085B (da) |
| IE (1) | IE60581B1 (da) |
| IL (1) | IL74948A (da) |
| NO (1) | NO851535L (da) |
| PT (1) | PT80301B (da) |
| ZA (1) | ZA852854B (da) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3342139A1 (de) * | 1983-11-22 | 1985-05-30 | Ciba-Geigy Ag, Basel | Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel |
| EP0168342B1 (de) * | 1984-06-14 | 1991-07-03 | Ciba-Geigy Ag | Verfahren zur Herstellung von Thrombin-Inhibitoren |
| DE3506992A1 (de) * | 1985-02-27 | 1986-08-28 | Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn | Modifizierte hirudine, verfahren zu deren herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten |
| DE3738541A1 (de) * | 1987-11-13 | 1989-05-24 | Hoechst Ag | Verfahren zur isolierung und reinigung von hirudin |
| EP0324712B1 (de) * | 1985-04-11 | 1993-04-07 | Hoechst Aktiengesellschaft | Hirudin-Derivat |
| DE3689525D1 (de) * | 1985-07-17 | 1994-02-24 | Hoechst Ag | Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel. |
| GB8530631D0 (en) | 1985-12-12 | 1986-01-22 | Ciba Geigy Ag | Thrombin inhibitors |
| US5789540A (en) * | 1987-01-23 | 1998-08-04 | Merrell Pharmaceuticals Inc. | Anticoagulant peptides |
| US6005071A (en) * | 1987-01-23 | 1999-12-21 | Merrell Pharmaceuticals Inc. | Anticoagulant peptides |
| PT87083B (pt) * | 1987-03-28 | 1992-07-31 | Boehringer Ingelheim Int | Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem |
| US5192745A (en) * | 1987-05-21 | 1993-03-09 | Merrell Dow Pharmaceuticals Inc. | Cyclic anticoagulant peptides |
| US5236898A (en) * | 1987-05-21 | 1993-08-17 | Merrell Dow Pharmaceuticals Inc. | Cyclic anticoagulant peptides |
| US5256559A (en) * | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| NZ228995A (en) * | 1988-05-10 | 1992-03-26 | Merrell Dow Pharma | Hirudin peptide derivatives and pharmaceutical compositions |
| US4971953A (en) * | 1988-05-10 | 1990-11-20 | Merrell Dow Pharmaceuticals | Anticoagulant peptide alcohols |
| DE68919848T2 (de) * | 1988-05-27 | 1995-05-04 | Philadelphia Children Hospital | Amphiphile peptide und deren verwendung. |
| US5114921A (en) * | 1988-05-27 | 1992-05-19 | The Children's Hospital Of Philadelphia | Amphiphilic peptides and use thereof |
| DE3819078A1 (de) * | 1988-06-04 | 1989-12-07 | Hoechst Ag | Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie |
| DE3819079A1 (de) * | 1988-06-04 | 1989-12-07 | Hoechst Ag | Hirudin-derivate mit verzoegerter wirkung |
| US5268296A (en) * | 1988-06-11 | 1993-12-07 | Ciba-Geigy Corporation | DNA vector and recombinant host cell for production of hirullin P6 and P18 |
| ES2052062T3 (es) * | 1988-06-11 | 1994-07-01 | Ciba Geigy Ag | Nuevos polipeptidos con actividad anticoagulante. |
| US5112615A (en) * | 1988-08-03 | 1992-05-12 | New England Deaconess Hospital Corporation | Soluble hirudin conjugates |
| US5167960A (en) * | 1988-08-03 | 1992-12-01 | New England Deaconess Hospital Corporation | Hirudin-coated biocompatible substance |
| DE3835815A1 (de) * | 1988-10-21 | 1990-04-26 | Hoechst Ag | Neue isohirudine |
| US4861865A (en) * | 1989-01-23 | 1989-08-29 | Washington University | Novel antithrombin peptide |
| US5254535A (en) * | 1989-04-17 | 1993-10-19 | The Children's Hospital Of Pennsylvania | Composition and treatment with biologically active peptides and antibiotic |
| US5179196A (en) * | 1989-05-04 | 1993-01-12 | Sri International | Purification of proteins employing ctap-iii fusions |
| US5192747A (en) * | 1989-10-03 | 1993-03-09 | Merrell Dow Pharmaceuticals Inc. | Anticoagulant peptides |
| DE3939801A1 (de) * | 1989-12-01 | 1991-06-06 | Basf Ag | Neue proteine und ihre herstellung |
| US5792831A (en) * | 1990-02-08 | 1998-08-11 | Magainin Pharmaceuticals Inc. | Analogues of magainin peptides containing D-amino acids |
| WO1991012015A1 (en) * | 1990-02-08 | 1991-08-22 | Magainin Sciences Inc. | Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell |
| US5459237A (en) * | 1990-02-08 | 1995-10-17 | Magainin Pharmaceuticals Inc. | Peptide compositions and uses therefor |
| AU641215B2 (en) * | 1990-02-13 | 1993-09-16 | Merrell Dow Pharmaceuticals Inc. | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
| DE4009268A1 (de) * | 1990-03-22 | 1991-09-26 | Consortium Elektrochem Ind | Sekretion von hirudinderivaten |
| EP0533795A4 (en) * | 1990-05-14 | 1993-10-20 | Magainin Sciences, Inc. | Composition of and treatment with biologically active peptides having d-amino acid residues |
| US5208220A (en) * | 1990-06-27 | 1993-05-04 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase |
| JPH05507718A (ja) * | 1990-06-27 | 1993-11-04 | マゲイニン サイエンセズ インコーポレーテッド | 生物活性ペプチドおよびｄｎａギラーゼを阻害する抗生物質よりなる組成物と治療法 |
| US5118790A (en) * | 1990-07-24 | 1992-06-02 | Sri International | Analogs of hirudin |
| US5574012A (en) * | 1990-07-24 | 1996-11-12 | Merrell Pharmaceuticals Inc. | Analogs of hirudin having anti-platelet activity |
| DK0540574T3 (da) * | 1990-07-24 | 1996-09-30 | Merrell Pharma Inc | Antikoagulationspeptider |
| US6514730B1 (en) * | 1991-03-21 | 2003-02-04 | Consortium für elektrochemische Industrie GmbH | Secretion of hirudin derivatives |
| AU2901692A (en) * | 1991-10-16 | 1993-05-21 | Children's Hospital Of Philadelphia, The | Composition and treatment with biologically active peptides and antibiotic |
| DE4140381A1 (de) * | 1991-12-07 | 1993-06-09 | Hoechst Ag, 6230 Frankfurt, De | Neue synthetische isohirudine mit verbesserter stabilitaet |
| CN1124964A (zh) * | 1993-06-11 | 1996-06-19 | 默里尔药物公司 | 三功能抗凝血酶和抗血小板的肽 |
| NZ270194A (en) * | 1994-01-07 | 1996-05-28 | Ciba Geigy Ag | Hirustasin, a serine protease inhibitor from hirudo medicinalis |
| GB9401447D0 (en) | 1994-01-26 | 1994-03-23 | Ciba Geigy Ag | Pharmaceutical compositions |
| DE4404168A1 (de) * | 1994-02-10 | 1995-08-17 | Hoechst Ag | Hirudinderivate und Verfahren zu deren Herstellung |
| DE19529997C1 (de) * | 1995-08-16 | 1997-04-10 | Hoechst Ag | Verfahren zur Inaktivierung von Carboxypeptidase Y in hirudinhaltigen Kulturbrühen |
| DE19543737A1 (de) * | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| DE19544233A1 (de) | 1995-11-28 | 1997-06-05 | Hoechst Ag | Verfahren zur Nutzung des Hefe-ADH II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten |
| DE69625623T2 (de) | 1996-01-31 | 2003-11-06 | Sumitomo Bakelite Co. Ltd., Tokio/Tokyo | Verfahren zur Herstellung von in Epoxyharz eingekapselter Halbleitervorrichtung |
| DE19607239A1 (de) | 1996-02-27 | 1997-08-28 | Behringwerke Ag | Pharmazeutische Zusammensetzung, enthaltend Hirudin und Verfahren zu deren Herstellung |
| US7795205B2 (en) * | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
| CN101095697A (zh) * | 2006-06-28 | 2008-01-02 | 李振国 | 水蛭和/或地龙分子量5800道尔顿以下的提取物 |
| US9056118B2 (en) * | 2007-06-26 | 2015-06-16 | Mudanjiang Youbo Pharmaceutical Co., Ltd. | Extract for preventing of treating thrombotic diseases |
| SG171340A1 (en) * | 2008-11-19 | 2011-07-28 | Avantor Performance Mat Inc | New chromatographic media based on phenoxy alkyl and alkoxy-or phenoxy-phenyl alkyl ligands |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3342139A1 (de) * | 1983-11-22 | 1985-05-30 | Ciba-Geigy Ag, Basel | Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel |
| CA1341414C (fr) * | 1984-03-27 | 2002-12-31 | Paul Tolstoshev | Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine |
| DE3429430A1 (de) * | 1984-08-10 | 1986-02-20 | Hoechst Ag, 6230 Frankfurt | Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens |
-
1984
- 1984-10-19 DE DE19843438296 patent/DE3438296A1/de not_active Withdrawn
-
1985
- 1985-04-11 HU HU851341A patent/HU198085B/hu not_active IP Right Cessation
- 1985-04-12 EP EP85104445A patent/EP0158986B1/de not_active Expired - Lifetime
- 1985-04-12 DE DE85104445T patent/DE3587576D1/de not_active Expired - Lifetime
- 1985-04-16 AR AR85300094A patent/AR242800A1/es active
- 1985-04-16 FI FI851521A patent/FI851521L/fi not_active Application Discontinuation
- 1985-04-16 ES ES542311A patent/ES8605772A1/es not_active Expired
- 1985-04-16 ES ES542310A patent/ES8605771A1/es not_active Expired
- 1985-04-16 ES ES542309A patent/ES542309A0/es active Granted
- 1985-04-17 IE IE98385A patent/IE60581B1/en not_active IP Right Cessation
- 1985-04-17 ZA ZA852854A patent/ZA852854B/xx unknown
- 1985-04-17 KR KR1019850002581A patent/KR930000054B1/ko not_active IP Right Cessation
- 1985-04-17 PT PT80301A patent/PT80301B/pt not_active IP Right Cessation
- 1985-04-17 NO NO851535A patent/NO851535L/no unknown
- 1985-04-17 GR GR850942A patent/GR850942B/el unknown
- 1985-04-17 IL IL74948A patent/IL74948A/xx not_active IP Right Cessation
- 1985-04-17 US US06/724,332 patent/US4668662A/en not_active Expired - Lifetime
- 1985-04-17 AU AU41364/85A patent/AU580295B2/en not_active Expired
- 1985-04-17 JP JP60080430A patent/JP2552263B2/ja not_active Expired - Lifetime
- 1985-04-17 DK DK173985A patent/DK171824B1/da not_active IP Right Cessation
- 1985-04-17 CA CA000479344A patent/CA1271298A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FI851521L (fi) | 1985-10-19 |
| KR850007801A (ko) | 1985-12-09 |
| ES542310A0 (es) | 1985-12-16 |
| AR242800A1 (es) | 1993-05-31 |
| IE60581B1 (en) | 1994-07-27 |
| PT80301B (de) | 1987-02-10 |
| DK173985A (da) | 1985-10-19 |
| ES542311A0 (es) | 1985-12-16 |
| EP0158986A3 (en) | 1988-09-21 |
| ZA852854B (en) | 1985-11-27 |
| JPS60233098A (ja) | 1985-11-19 |
| KR930000054B1 (ko) | 1993-01-06 |
| HUT37806A (en) | 1986-02-28 |
| AU4136485A (en) | 1985-10-24 |
| FI851521A0 (fi) | 1985-04-16 |
| DE3438296A1 (de) | 1985-11-07 |
| IL74948A (en) | 1989-09-10 |
| HU198085B (en) | 1989-07-28 |
| AU580295B2 (en) | 1989-01-12 |
| CA1271298A (en) | 1990-07-03 |
| PT80301A (de) | 1985-05-01 |
| US4668662A (en) | 1987-05-26 |
| JP2552263B2 (ja) | 1996-11-06 |
| GR850942B (da) | 1985-11-25 |
| DK173985D0 (da) | 1985-04-17 |
| IE850983L (en) | 1985-10-18 |
| ES8605770A1 (es) | 1985-12-16 |
| DE3587576D1 (de) | 1993-10-21 |
| ES8605771A1 (es) | 1985-12-16 |
| IL74948A0 (en) | 1985-08-30 |
| EP0158986B1 (de) | 1993-09-15 |
| ES542309A0 (es) | 1985-12-16 |
| DK171824B1 (da) | 1997-06-23 |
| ES8605772A1 (es) | 1985-12-16 |
| EP0158986A2 (de) | 1985-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO851535L (no) | Nye polypeptider med blodkoaguleringshemmende virkning, fremgangsmaate til deres fremstilling resp. utvinnelse, deres anvendelse og midler inneholdende disse | |
| DK173509B1 (da) | Polypeptider med blodkoaguleringshæmmende virkning, deres fremstilling eller udvinding samt midler med indhold deraf | |
| CA1239606A (en) | Desulfatohirudins, the preparation thereof and pharmaceutical compositions containing them | |
| Charles et al. | The primary structure of porcine colipase II. I. The amino acid sequence | |
| EP0147193B1 (en) | Peptide production and use thereof | |
| US4003884A (en) | Peptides having LH-RH/FSH-RH activity | |
| US4656158A (en) | Peptide, and production and use thereof | |
| RU2050160C1 (ru) | Полипептид, полученный из ткани или секрета пиявок hirudinaria manillensis, специфически ингибирующий тромбин | |
| CA1137467A (en) | Process for the preparation of somatostatin | |
| IE59400B1 (en) | Peptide amino-alcohol derivatives containing a tetra-substituted carbon atom, inhibitors of renin and of acid preteases, preparation process and pharmaceutical compositions. | |
| LU85710A1 (fr) | Nouveaux derives de la gonadoliberine et procede pour leur preparation | |
| CA1249396A (en) | Partially retro-inverted decapeptide as a specific renin inhibitor with high resistance to enzymatic hydrolysis | |
| Akaji et al. | Efficient synthesis of peptaibol using a chloroimidazolidium coupling reagent, CIP | |
| Bernard et al. | Synthesis of conjugates between luteinizing hormone releasing hormone (LH‐RH) and N‐acetyl‐muramyl‐L‐alanyl‐D‐isoglutamine (MDP) models of totally synthetic vaccines | |
| US5322926A (en) | Isohirudins | |
| US4784988A (en) | Peptides correlated to lysozyme | |
| RU2086561C1 (ru) | Способ получения нонапептидэтиламида | |
| Bentley et al. | 1176. Polypeptides. Part I. The synthesis of peptides related to eledoisin | |
| UEDA et al. | Synthesis of the hexadecapeptide corresponding to positions 1 through 16 of porcine motilin, a gastric motor activity stimulating polypeptide | |
| Katsoyannis et al. | Insulin peptides. XVIII. Synthesis of a partially protected heneicosapeptide containing the C-terminal sequence of the B chain of insulin | |
| Beddell et al. | Pseudosymmetry in the structure of luteinizing hormone-releasing hormone. Series of novel analogs | |
| JPH05331190A (ja) | 新規ペプチド及びその製造方法 | |
| JPH08333389A (ja) | ヘキサペプチドの製造方法 | |
| JPH0959296A (ja) | 新規なテトラペプチドおよびアンジオテンシン変換酵素 阻害剤 | |
| Abiko et al. | Synthesis of [Phe (4F) 3] thymopoietin II and examination of its immunological effect on the impaired blastogenic response of T-lymphocytes of uremic patients |